



GP1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Yu Ren et al.

Serial No. 10/607,114

Filed: June 26, 2003

For: SALT FORMS WITH TYROSINE KINASE ACTIVITY

Art Unit: 1614

Examiner:

Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT
 UNDER 37 CFR 1.97**

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.
 By Axline Brown Date 11/3/03



INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

the attached information is filed within three months of the filing date of the captioned case.

the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.

the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).

the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,


 By: Dianne Brown
 Attorney For Applicant(s)
 Reg. No. 42,068
 MERCK & CO., INC.
 Patent Dept., RY60-30
 P.O. Box 2000
 Rahway, N.J. 07065-0907
 (732)594-1249
 Date: November 3, 2003

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p> <p style="text-align: center;">NOV 06 2003</p> <p>U.S. PATENT & TRADEMARK OFFICE</p>		COMPLETE IF KNOWN	
		Application Number	10/607,114
		Filing Date	June 26, 2003
		First Named Inventor	Yu Ren et al.
		Group Art Unit	1614
		Examiner Name	
Sheet	1	of	7
		Attorney Docket Number	21068

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
		EPO	1040831 A2		Pfizer Products Inc.	10/04/2000
		PCT	WO 95/33750		Pfizer Inc.	12/14/1995
		PCT	WO 00/62778		Bristol-Myers Squibb Co.	10/26/2000
		PCT	WO 00/39101		AstraZeneca	07/06/2000
		PCT	WO 95/09847		Ciba-Geigy AG	04/13/1995
		PCT	WO 00/12497		Scios Inc.	03/09/2000
		PCT	WO 95/35275		British Biotech Pharma Ltd.	12/28/1995
		PCT	WO 00/09495		Novartis AG	02/24/2000
		PCT	WO 97/44326		Hoffmann-La Roche AG	11/27/1997
		PCT	WO 97/19065		Celltech Therapeutics Ltd	05/29/1997

Examiner Signature _____ Date Considered _____

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder). Merck & Co., Inc., 09/05/2003

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

NOV 06 2003

(as many sheep as necessary)

Sheet

1

of

7

Attorney Docket Number 21068

21068

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
		PCT	WO 95/35276		British Biotech Pharma. Ltd.	12/28/1995
		PCT	WO 95/09852		Ciba-Geigy AG	04/13/1995
		PCT	WO 99/65884		Bristol-Myers Squibb Co.	12/23/1999
		PCT	WO 94/01423		Nippon Soda Co., Ltd.	01/20/1994
		PCT	WO 99/64418		Novartis AG	12/16/1999
		EPO	0 564 409 A1		Ciba-Geigy AG	10/06/1993
		JP	7149745 A		Torii Yakuhin	06/13/1995
		JP	6475475 A		Hisamitsu Pharm.	03/22/1989
		DE	19824175 A1		Novartis AG	05/29/1998
		EPO	0 384 250		Bayer AG	08/29/1990

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)	
		DE	19548415	Bayer AG	06/22/1997
		PCT	WO 01/56567	Novo Nordisk A/S	08/09/2001
		PCT	WO 01/70738	Merck Frosst Canada & Co.	06/27/2001
		PCT	WO 01/17995	Merck & Co., Inc.	03/15/2001
		PCT	WO 99/65884	Bristol-Myers SquibbCo.	12/23/1999
		PCT	WO 99/21845	Agouron Pharmaceuticals, Inc.	05/06/1999
		PCT	WO 98/32753	Merck & Co., Inc.	07/30/1998

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO				COMPLETE IF KNOWN	
INFORMATION DISCLOSURE				Application Number	10/607,114
STATEMENT BY APPLICANT				Filing Date	June 26, 2003
NOV 06 2003 (Patent & Trademark Office) (as many sheets as necessary)				First Named Inventor	Yu Ren et al.
				Group Art Unit	1614
				Examiner Name	
Sheet	4	of	7	Attorney Docket Number	21068

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
		J. Rak et al. Cancer Research, 55:4575-4580, 1995			
		G. Gasparini and A.L. Harris, J. Clin. Oncol., 1995, 13:765-782			
		M. Toi et al., Japan. J. Cancer Res., 1994, 85:1045-1049			
		A.J. Dickinson et al., Br. J. Urol., 1994, 74:762-766			
		L.M. Ellis et al., Surgery, 1996, 120(5):871-878			
		J.K. Williams et al., Am. J. Surg., 1994, 168:373-380			
		A. Amirkhosravi et al., Platelets, 10:285-292 (1999)			
		S.P. Gunningham, et al., Can. Research, 61: 3206-3211 (2001)			
		A. Giatromanolaki et al., J. Pathol. 2001; 194:101-108			
		Michael Detmar, J. Dermatological Sci., 24 Suppl. 1, S78-S84 (2000).			
		Hasegawa et al., Skeletal Radiol., Vol. 28, pp.41-45, 1999			
		Brockelsby et al., Laboratory Investigation 79:1101-1111 (September 1999)			
		Paul et al., Nature Med 7:222-227 (2001).			
		Matsuyama et al., J. Neurol. Sci. 186:75-79 (2001)			
		van der Flier et al., J. Infectious Diseases, 183:149-153 (2001)			

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

NOV 06 2003
U.S. PATENT & TRADEMARK OFFICE

Sheet	5	of	7	Attorney Docket Number	21068
-------	---	----	---	------------------------	-------

COMPLETE IF KNOWN

Application Number	10/607,114
Filing Date	June 26, 2003
First Named Inventor	Yu Ren et al.
Group Art Unit	1614
Examiner Name	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Stephen K. Smith, Trends in Endocrinology & Metabolism, Vol. 12, No. 4, pp. 147-151, May/June 2001
		Levis et al., Blood, Vol. 98, No. 3, pp.885-887 (2001)
		Rajesh K. Jain, Nature Medicine, Vol. 7. No. 9, pp. 987-989 (September 2001)
		Giulio Jori, Lasers Med. Sci., 1990; 5: 115-120
		Chuannong Zhou, J. Photochem. and Photobiol. 1989; 3: 299-318
		Hendrich et al., Knee Surg Sports Traumatol Arthroscopy 5: 58-63 (1997).
		Hall et al., Am J Hum Genet 61:785-789, 1997
		Li et al., Gene Therapy, 1998; 5:1105-1113
		Fathallah-Shaykh et al., J Immunol 2000; 164:217-222
		Dougherty et al., J. Natl. Cancer Inst., 1998, 90(12): 889-905
		Van Bruggen et al., J. Clin. Invest., 104:1613-1620 (1999)
		Gerber et al., Nature Medicine, Vol. 5, No. 6, pp.623-628, 1999
		David A. Greenberg, Drug News Perspect 11(5):265-270 (1998)
		Nakagawa et al., FEBS Let. 473:161-164 (2000)
		M. Shibuya, et al., Oncogene, Vol. 5, pp. 519-524 (1990)

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)



COMPLETE IF KNOWN

Application Number	10/607,114		
Filing Date	June 26, 2003		
First Named Inventor	Yu Ren et al.		
Group Art Unit	1614		
Examiner Name			
Sheet	6	of	7
Attorney Docket Number 21068			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Stem Cells, Vol. 12, pp. 1-6 (1994), by T. R. Burke, Jr.
		Molecular Cell, Vol. 4, pp. 915-924 (1999), by B. Eliceiri, et al.
		Oncogene, Vol. 6, pp. 1677-1683 (1991), by B. Terman, et al.
		Nature Biotech., Vol. 17, pp. 963-968 (1999), by V. Brower
		Nature, Vol. 407, pp. 242-248 (2000), by G. Yancopoulos, et al.
		Nature, Vol. 407, pp. 249-257 (2000), by P. Carmeliet, et al.
		Endocrinology, Abstract, Vol. 141, No. 5, pp. 1667-1674 (2000), by M. Deckers, et al.
		Chem. Abst., Vol. 109, No. 8, pg. 634 (1988), N. A. Shvink
		Chem. Abstr., Vol. 111, No. 15, pg. 761 (1989), by M. Tsuji
		Chem. Abstr., Vol. 111, No. 21, pg. 765 (1989), by M. Santus
		Chem. Abstr., Vol. 126, No. 21, pg. 666 (1997), by C. S. Ra
		Chem. Abstr., Vol. 101, No. 11, pg. 33 (1984), by H. Nagatomi
		Abstract, Indian J. Chem., Sect. G (1986), 25B(4), 452-5, S.E. Kulkarni, et al.
		Abstract, Eur. Pat. Appl., 35 pp., T. Takaya, et al.
		Abstract, Acta Pol. Pharm. (1980), 37(3), 293-300, M. Santus

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO			COMPLETE IF KNOWN	
INFORMATION DISCLOSURE			Application Number	10/607,114
STATEMENT BY APPLICANT			Filing Date	June 26, 2003
(use as many sheets as necessary)			First Named Inventor	Yu Ren et al.
			Group Art Unit	1614
			Examiner Name	
Sheet	7	of	7	Attorney Docket Number
21068				

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Abstract, Res. Commun., (1982), 14(4), 359-68, M. Tandon, et al.
		Abstract, Pharmazie (1975), 30(3), 141-7, G. Wagner, et al.
		Annual Reports in Med. Chem., Vol. 27, pp. 139-148 (1992), Mitchell, et al.
		Abstract, Hematol Oncol. Clin. North Am., 2002, Oct; 16(5) 1173-87, Rosen.
		Abstract, Pharmacol. Ther. 1998, Feb. 77(2): 81-114, Lawrence et al.
		Ann. NY Acad. Sci. 979: 80-93 (2002), Luttun et al.
		Cancer Research, 60, 970-975, Feb. 15, 2000, Wedge et al.
		Exp. Opin. Ther. Patents, Vol. 7(6), 571-588, 1997, Traxler.
		Cecil Textbook of Medicine, 20th Edition, vol. 1, 1004-10, 1996, Simone.

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003